PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: €32.50 through €230.00
Tesamorelin EU – Buy Online | In Stock & Ready to Ship
Buy Tesamorelin in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for Tesamorelin Europe suppliers, looking to buy Tesamorelin in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
Tesamorelin is a synthetic full-length GHRH analogue peptide and the only research compound retaining the complete 44-amino acid native growth hormone releasing hormone sequence with DPP-IV stabilisation — making it the reference full-length GHRH receptor agonist available to laboratories across Europe for GH axis research, visceral adipose biology, and comparative GHRH analogue pharmacology studies. Research institutions and laboratories across the EU can source verified, research-grade Tesamorelin in Europe with fast dispatch and full batch documentation included.
Available Sizes: 2mg | 5mg | 10mg
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch Across EU & Europe | EU Peptides Stock
Tesamorelin is a stabilised analogue of full-length human growth hormone releasing hormone — the hypothalamic peptide that signals the pituitary gland to release growth hormone. Unlike other GHRH research peptides available in Europe such as Sermorelin and Modified GRF(1-29), which are truncated at 29 amino acids, Tesamorelin retains the complete 44-amino acid native GHRH sequence — the full length of endogenous human GHRH.
The key structural modification in Tesamorelin is the addition of a trans-3-hexenoic acid group to the N-terminus of the peptide. This short-chain fatty acid conjugation sterically shields the Tyr1-Ala2 bond that would normally be cleaved within seconds by the DPP-IV enzyme — extending the circulating half-life from seconds to approximately 26–38 minutes without altering any amino acid in the native GHRH sequence itself. This is pharmacologically significant because it means Tesamorelin activates the GHRH receptor with the complete native 44-residue pharmacophore geometry — a research capability unavailable from any truncated GHRH analogue.
Tesamorelin received FDA approval as Egrifta for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy — making it the most clinically validated full-length GHRH analogue available as a research compound in Europe, with an extensive human pharmacology and safety dataset supporting its translational research relevance.
In controlled laboratory and pre-clinical research settings across EU and European institutions, Tesamorelin is studied across GHRH receptor pharmacology, GH secretion biology, visceral fat metabolism, somatotroph regulatory biology, and comparative GHRH analogue applications:
Full-Length GHRH Receptor Pharmacology — Tesamorelin is the only available research peptide that activates the GHRH receptor with the complete 44-amino acid native GHRH sequence. Research uses it to characterise GHRHR binding with the intact full-length pharmacophore, Gs-cAMP-PKA signal transduction, and whether the C-terminal GHRH domain residues 30–44 — absent from all truncated GHRH analogues — contribute pharmacologically meaningful differences to receptor engagement relative to Sermorelin and Modified GRF(1-29).
GH Secretion and Pituitary Somatotroph Biology — Tesamorelin stimulates pituitary somatotroph cells to release growth hormone through GHRH receptor activation — producing episodic GH pulses with a duration intermediate between short-acting native GHRH and long-acting CJC-1295 With DAC. Research uses Tesamorelin to study GH pulse kinetics, somatotroph secretory reserve, and the physiological regulation of GH release under full-length GHRH receptor stimulation.
Visceral Adipose Tissue Biology — Tesamorelin’s FDA approval for visceral fat reduction establishes visceral adipose biology as its primary translational research application across EU institutions. Research has characterised Tesamorelin-driven GH axis restoration and its downstream effects on selective visceral fat mobilisation — examining the mechanisms of GH-preferential visceral versus subcutaneous adipose depot lipolysis, the contribution of IGF-1 axis activation to net visceral fat reduction outcomes, and the neuroendocrine basis of somatotropic axis dysregulation in lipodystrophy and metabolic disease models.
GH Axis Integrity Assessment — Tesamorelin stimulation testing is used in pre-clinical research to assess somatotroph secretory reserve — characterising peak GH responses as a functional readout of pituitary GH axis integrity across disease models, ageing paradigms, and pharmacological intervention studies. This application mirrors the clinical diagnostic use of GHRH stimulation testing in human GH deficiency assessment.
HIV Lipodystrophy and Metabolic Disease Research — Tesamorelin’s clinical approval context provides a specific and well-characterised metabolic disease research framework — studying antiretroviral-associated GH axis dysregulation, the neuroendocrine basis of visceral fat accumulation under protease inhibitor therapy, and the restoration of GH pulse biology and metabolic normalisation through GHRHR stimulation.
Comparative GHRH Analogue Pharmacology — Tesamorelin is studied alongside Sermorelin, Modified GRF(1-29), and CJC-1295 With DAC in comparative pharmacology protocols across European research groups — establishing how the complete 44-residue GHRH sequence, the trans-3-hexenoic acid N-terminal modification, and the resulting intermediate half-life produce pharmacologically distinct or equivalent GH secretory outcomes relative to truncated and long-acting GHRH analogues.
GHRH-GHS Synergy Research — Tesamorelin produces synergistic GH release when co-administered with GHS-R1a agonists including GHRP-6, GHRP-2, and Ipamorelin — through complementary Gs-cAMP and Gq/11-calcium somatotroph signalling pathway interactions. Research uses Tesamorelin as the full-length GHRHR synergy component to characterise whether the complete GHRH sequence modifies synergistic GH responses relative to truncated GHRH analogues.
IGF-1 Axis Biology — Tesamorelin-driven GH release activates the downstream hepatic IGF-1 production axis — making it a research tool for studying GH-IGF-1 axis biology under full-length native-sequence GHRHR stimulation conditions producing physiologically patterned episodic GH pulses.
Research and clinical investigation have produced a well-characterised profile for Tesamorelin across GH axis biology and visceral fat metabolism:
Tesamorelin’s FDA approval as Egrifta followed Phase III clinical trials demonstrating significant visceral adipose tissue reduction in HIV lipodystrophy patients — establishing it as the only approved pharmacological treatment for this condition and providing the most extensive human pharmacology dataset of any full-length GHRH analogue available to European researchers.
Clinical studies documented Tesamorelin’s restoration of GH pulse amplitude and frequency in HIV lipodystrophy patients characterised by GH hyposecretion — confirming its pharmacological validity as a GHRH receptor agonist capable of restoring physiological GH secretory patterns in states of hypothalamic GHRH deficiency.
Visceral selectivity research documented preferential reduction of visceral adipose tissue without peripheral fat loss — consistent with GH’s well-characterised depot-selective lipolytic biology and establishing Tesamorelin as the reference GHRH analogue for studying somatotropic axis regulation of visceral adiposity.
The trans-3-hexenoic acid DPP-IV resistance mechanism has been pharmacokinetically validated — confirming substantially extended plasma stability relative to native GHRH(1-44) and establishing the steric protection mechanism as a viable N-terminal modification strategy for full-length GHRH sequence stabilisation.
IGF-1 elevation consistent with restored GH axis activity has been documented in Tesamorelin-treated subjects — confirming that GHRHR-driven GH release translates into meaningful downstream IGF-1 axis activation appropriate for research protocols examining the anabolic and metabolic consequences of GH axis restoration.
Cardiovascular risk marker improvements alongside visceral fat reduction have been documented in clinical research — including triglyceride reduction and HDL cholesterol improvement — contributing to characterisation of the broader metabolic consequences of GHRH-driven GH axis restoration beyond adipose tissue composition changes alone.
| Peptide | GHRH Sequence Length | Half-Life | DPP-IV Resistance | Key Research Distinction |
|---|---|---|---|---|
| Tesamorelin | Full 44 amino acids | ~26–38 minutes | Yes — trans-3-hexenoic acid N-terminal | Only full-length DPP-IV stabilised GHRH — C-terminal domain research — visceral fat biology |
| Sermorelin Acetate | 29 amino acids | ~10–12 minutes | No — native sequence labile | Native-sequence physiological reference — minimal active GHRH domain — FDA approved |
| Modified GRF(1-29) | 29 amino acids | ~30 minutes | Yes — Ala8 substitution | Proteolytically stabilised truncated GHRH — intermediate half-life |
| CJC-1295 With DAC | 29 amino acids | ~6–8 days | Yes — Ala8 + albumin shielding | Only long-acting GHRH — multi-day GH axis stimulation |
| Native GHRH(1-44) | Full 44 amino acids | Seconds | No — rapidly degraded | Endogenous reference — impractical for in vivo use |
| Parameter | Specification |
|---|---|
| Full Name | Tesamorelin |
| Also Known As | TH9507 / Egrifta (clinical formulation) / trans-3-hexenoic acid-GHRH(1-44)NH₂ |
| Type | Synthetic Full-Length GHRH(1-44) Analogue — Trans-3-Hexenoic Acid N-Terminal Modified — DPP-IV Resistant |
| Sequence Length | 44 amino acids — complete native GHRH sequence |
| N-Terminal Modification | Trans-3-hexenoic acid — steric DPP-IV resistance without amino acid substitution |
| Molecular Weight | ~5135.9 Da |
| Mechanism | GHRHR Gs-cAMP-PKA → GH gene transcription + GH granule exocytosis — full 44-residue native GHRH pharmacophore |
| Half-Life | ~26–38 minutes |
| Clinical Approval | FDA approved — Egrifta for HIV lipodystrophy visceral fat reduction |
| Purity | ≥99% HPLC & MS Verified |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water or 0.1% acetic acid aqueous solution |
| Storage (Powder) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | -80°C single-use aliquots — minimise freeze-thaw cycles |
| Available Sizes | 2mg, 5mg, 10mg |
| Dispatch | Fast EU & Europe dispatch |
| Intended Use | Research use only |
Every order of Tesamorelin dispatched across the EU and Europe includes:
✅ Batch-Specific Certificate of Analysis (CoA)
✅ HPLC Chromatogram
✅ Mass Spectrometry Confirmation — including trans-3-hexenoic acid modification integrity verification
✅ Sterility & Endotoxin Testing Report
✅ Reconstitution Protocol — including Met and Tyr oxidation protection guidance
✅ Technical Research Support
Yes — research-grade Tesamorelin is available to researchers and institutions across the EU and Europe with fast dispatch and full batch documentation included. Supplied strictly for laboratory research purposes only.
Tesamorelin retains the complete 44-amino acid native GHRH sequence — all other GHRH analogue research peptides available in Europe including Sermorelin and Modified GRF(1-29) are truncated at 29 amino acids. The trans-3-hexenoic acid N-terminal modification provides DPP-IV resistance through steric shielding without altering any amino acid in the native sequence — preserving the complete GHRH pharmacophore while extending half-life to a practical research window.
Trans-3-hexenoic acid is a short-chain unsaturated fatty acid conjugated to the N-terminal amino group of Tesamorelin’s Tyr1 residue. It works by physically blocking the DPP-IV enzyme from accessing and cleaving the Tyr1-Ala2 bond that would otherwise rapidly degrade the peptide in circulation. Crucially it does this without substituting any amino acid — so the native GHRH sequence is preserved intact beneath the N-terminal modification.
The primary research applications across EU laboratories include full-length GHRH receptor pharmacology, visceral adipose tissue biology and GH-driven fat mobilisation research, GH axis integrity assessment using Tesamorelin stimulation testing paradigms, HIV lipodystrophy and antiretroviral-associated metabolic disease research, and comparative GHRH analogue pharmacology establishing the pharmacological consequences of full-length versus truncated GHRH sequence receptor engagement.
Tesamorelin retains the full 44-amino acid GHRH sequence and has a half-life of 26–38 minutes — producing episodic GH pulses suitable for physiological GH secretion research. CJC-1295 With DAC is a truncated 29-amino acid GHRH analogue with a DAC albumin-binding linker extending its half-life to 6–8 days — producing sustained multi-day GH elevation suited to chronic GH axis stimulation research. They occupy pharmacodynamically distinct positions in the GHRH analogue research toolkit.
Vehicle controls in matched buffer, GHRHR antagonist controls confirming receptor specificity, Sermorelin at equivalent molar concentrations as the 29-residue truncated GHRH comparative reference, and trans-3-hexenoic acid alone to confirm absence of N-terminal modification-intrinsic biological activity. For visceral fat studies, GH receptor antagonist controls confirm that adipose outcomes are GH-mediated rather than direct GHRHR-adipocyte effects.
≥99% purity by HPLC and mass spectrometry is essential — trans-3-hexenoic acid hydrolysis products restoring DPP-IV susceptibility, Met oxidation variants, and C-terminal truncation fragments would show substantially altered half-life, receptor binding, and GH secretory potency. Trans-3-hexenoic acid modification integrity verification by mass spectrometry is a critical specification. All Tesamorelin supplied for European research is verified to ≥99% purity with modification integrity confirmed.
Tesamorelin is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments across the EU and Europe. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in vitro or pre-clinical research purposes.
Receive News
